New Metal-Based Drugs for Cancer Treatment: Single Molecules, Nanomaterials, and Beyond

Dear Colleagues,

The search for new therapeutic alternatives to combat cancer has found in the transition elements a very abundant source of compounds and nanostructures with different geometric arrangements and reactivity that provide unique opportunities to interact with varying sites of recognition and exert mechanisms of action other than those drugs that are currently used to kill tumor cells. These features not only provide new tools independently but also could provide advantages enhancing concomitantly or sequentially the effect of known antineoplastic agents. In this Topic, the most recent findings regarding preclinical studies of metallodrugs, including but not limited to synthesis, characterization, simulation, computational modeling, and theoretical approach to new antiproliferative and antitumor agents, qualitative/quantitative structure-activity studies, bio-speciation/bioaccumulation, interaction with specific enzymes and nucleic acids, cytotoxicity, genotoxicity, teratogenicity, and general toxicity will be outlined. Submissions of original papers and focused reviews are welcome.

Dr. Juan Carlos García-Ramos
Dr. Yanis Toledano-Magaña
Dr. Gener José Avilés Rodríguez
Dr. Rodrigo Galindo-Murillo
Topic Editors